Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma
Abstract Introduction Avelumab and pembrolizumab are approved immune checkpoint inhibitors (ICIs) for advanced urothelial carcinoma (UC) that are used as maintenance and salvage therapies, respectively. The aim of this study was to highlight patterns of extreme response and support the development o...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Adis, Springer Healthcare
2025-10-01
|
| سلاسل: | Oncology and Therapy |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1007/s40487-025-00387-7 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|